We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-12.75%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$189M
AUM Growth
-$23.4M
Cap. Flow
+$27.5M
Cap. Flow %
14.56%
Top 10 Hldgs %
53.8%
Holding
36
New
10
Increased
6
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
AKBA icon
Akebia Therapeutics
AKBA
+$10.2M
2
PCVX icon
Vaxcyte
PCVX
+$9.24M
3
IMVT icon
Immunovant
IMVT
+$7.84M
4
ASND icon
Ascendis Pharma A/S
ASND
+$7.14M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$6.45M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$8.35M
2
KALV
KalVista Pharmaceuticals
KALV
+$7.89M
3
JSPR icon
Jasper Therapeutics
JSPR
+$6.89M
4
ORKA
Oruka Therapeutics
ORKA
+$4.44M
5
DVAX
Dynavax Technologies
DVAX
+$3.49M

Sector Composition

Rank Sector Weight
1 Healthcare 97.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.5B
$14.9M 7.88%
370,000
+10,000
+3% +$460K
KALV
2
DELISTED
KalVista Pharmaceuticals
KALV
$11.7M 6.2%
1,014,367
-772,636
-43% -$7.89M
EOLS icon
3
Evolus
EOLS
$385M
$11.4M 6.02%
944,743
+49,219
+5% +$644K
ABVX
4
Abivax
ABVX
$10.9B
$10.2M 5.42%
1,638,111
-10,412
-0.6% -$70.5K
VRDN icon
5
Viridian Therapeutics
VRDN
$2.09B
$10.1M 5.36%
750,000
– –
MRUS
6
DELISTED
Merus
MRUS
$9.98M 5.29%
237,156
+79,064
+50% +$3.45M
AKBA icon
7
Akebia Therapeutics
AKBA
$354M
$9.55M 5.06%
+4,973,840
New +$10.2M
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.06B
$8.23M 4.36%
245,272
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16B
$7.79M 4.13%
+50,000
New +$7.14M
DVAX
10
DELISTED
Dynavax Technologies
DVAX
$7.73M 4.09%
595,879
-264,121
-31% -$3.49M
IONS icon
11
Ionis Pharmaceuticals
IONS
$8.6B
$7.54M 4%
250,000
-255,007
-50% -$8.35M
AMLX icon
12
Amylyx Pharmaceuticals
AMLX
$2.26B
$6.41M 3.4%
+1,811,996
New +$6.45M
IMVT icon
13
Immunovant
IMVT
$7.93B
$6.41M 3.39%
+375,000
New +$7.84M
UNCY icon
14
Unicycive Therapeutics
UNCY
$137M
$6.31M 3.34%
1,098,000
– –
NGNE icon
15
Neurogene
NGNE
$656M
$5.51M 2.92%
470,964
+28,203
+6% +$490K
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.84B
$4.99M 2.64%
275,000
– –
SMMT icon
17
PUT
Summit Therapeutics
SMMT
$10.4B
$4.82M 2.55%
+250,000
New +$5.02M
LEGN icon
18
Legend Biotech
LEGN
$3.59B
$4.69M 2.48%
+138,240
New +$4.96M
PCVX icon
19
Vaxcyte
PCVX
$7.81B
$4.36M 2.31%
+115,517
New +$9.24M
AUTL
20
Autolus Therapeutics
AUTL
$397M
$4.23M 2.24%
2,728,910
-280,482
-9% -$569K
BBOT
21
BridgeBio Oncology
BBOT
$648M
$4.22M 2.24%
373,833
-126,167
-25% -$1.36M
ZURA icon
22
Zura Bio
ZURA
$516M
$4.09M 2.17%
3,170,194
– –
BEAM icon
23
Beam Therapeutics
BEAM
$2.63B
$3.43M 1.82%
+175,562
New +$4.6M
ACLX
24
DELISTED
Arcellx
ACLX
$2.95M 1.56%
+45,000
New +$3.05M
MREO
25
Mereo BioPharma
MREO
$54.7M
$2.87M 1.52%
1,275,000
+125,000
+11% +$354K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Great Point Partners held 36 positions worth $189M, down 11% from $212M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Great Point Partners deployed $27.5M of net new capital in Q1 2025, opening 10 new positions and adding to 6 existing holdings. Its largest new stake was Akebia Therapeutics: 4,973,840 shares worth $9.55M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $8.35M trimmed.

  • Great Point Partners's largest Q1 2025 buy was Akebia Therapeutics: 4,973,840 shares worth $9.55M.
  • Great Point Partners added most to Merus in Q1 2025, an estimated $3.45M increase.
  • Great Point Partners's biggest Q1 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $8.35M.
  • Great Point Partners fully exited Jasper Therapeutics in Q1 2025, selling an estimated $6.89M.
  • Great Point Partners's ten largest holdings make up 54% of its $189M portfolio in Q1 2025.
  • Great Point Partners opened 10 new positions and closed 4 in Q1 2025.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $189M.

Based on Great Point Partners's 13F filing for Q1 2025, filed 15 May 2025.